Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Jason Adair sold 688 shares of the company's stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $41.65, for a total transaction of $28,655.20. Following the completion of the transaction, the insider directly owned 214,738 shares in the company, valued at $8,943,837.70. The trade was a 0.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Jason Adair also recently made the following trade(s):
- On Monday, April 13th, Jason Adair sold 7,301 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total transaction of $280,139.37.
Liquidia Stock Up 1.3%
Shares of NASDAQ:LQDA opened at $38.15 on Thursday. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. The firm has a market capitalization of $3.39 billion, a PE ratio of -45.96 and a beta of 0.45. The firm's 50-day moving average is $36.38 and its two-hundred day moving average is $34.13. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $46.67.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The company had revenue of $92.02 million for the quarter, compared to analyst estimates of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. Liquidia's revenue for the quarter was up 3072.4% compared to the same quarter last year. Analysts predict that Liquidia Corporation will post 1.75 EPS for the current year.
Institutional Investors Weigh In On Liquidia
Large investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Liquidia in the fourth quarter valued at approximately $25,000. Covestor Ltd lifted its holdings in shares of Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company's stock worth $42,000 after purchasing an additional 359 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Liquidia during the third quarter worth $30,000. FNY Investment Advisers LLC acquired a new stake in shares of Liquidia during the third quarter worth $34,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Liquidia during the second quarter worth $25,000. 64.54% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research firms recently weighed in on LQDA. Jefferies Financial Group upped their target price on shares of Liquidia from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, January 13th. Oppenheimer upped their target price on shares of Liquidia from $16.00 to $19.00 and gave the stock an "underperform" rating in a research note on Thursday, March 12th. Raymond James Financial restated a "strong-buy" rating on shares of Liquidia in a research note on Thursday, March 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Liquidia in a report on Tuesday, April 21st. Finally, Wells Fargo & Company upped their price target on Liquidia from $44.00 to $51.00 and gave the company an "overweight" rating in a report on Monday, March 23rd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.44.
View Our Latest Analysis on LQDA
About Liquidia
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
